Infirmacea Inc.

A biotech company dedicated to transforming healthcare through innovative gene therapies. Our mission is to extend healthy lifespans and create a future where aging is synonymous with vitality. Our Vision: To revolutionize healthcare by providing accessible and effective gene therapies that address a wide range of diseases. Our Approach: Infirmacea's innovative fat-directed DNA therapy involves injecting DNA into subcutaneous fat, transforming it into a "health engine", promoting disease resistance. Since fat is abundant and easily accessible by injection, it serves as an ideal target for gene therapy, making this approach both efficient and practical. Key Technologies: 1. Human Fat Culture System (exFat): A proprietary platform that enables to discover “real human” outcome by interventions. 2. Gene Expression Enhancer (gBoost): A revolutionary technology for boosting cell-selective gene expression regardless of delivery systems (viral or non-viral). Product development: 1. Initial Focus: Obesity and Muscle Loss 2. Market Opportunity: Capitalizing on the rapidly growing anti-obesity market, driven by the success of GLP-1 drugs like Ozempic, Wegovy, and Zepbound. 3. Product Development: Developing a gene therapy product to address muscle loss, a common drawback of GLP-1 therapies. 4. Strategic Approach: Initially focusing on combination therapy with GLP-1 drugs to expedite market entry and subsequently exploring standalone therapy. Current focus: Seeking for gBoost licensing opportunities to gene therapy companies, particularly those working with adeno-associated virus (AAV) Future Directions: Expanding Indications: Identifying additional target genes for age-related muscle loss, using human fat samples from various age groups.